Antibodies are the type of globular proteins produced by the plasma cells. Polyclonal antibodies are produced by different types of plasma B cells and bind to different epitopes in the same antigen. Polyclonal antibodies are heterogeneous mixture of antibodies and are inexpensive to produce. Polyclonal antibodies are used in therapeutics as well as in research applications.
Market Dynamics
Rising incidence of cancer is expected to drive the global polyclonal antibody market growth. For instance, according to an article published by the Cancer Research UK, 367,167 new cases of cancer were reported between 2015 and 2017 in the U.K.
Moreover, ongoing development of polyclonal antibodies is expected to drive the market growth. For instance, in March 2020, GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced that the company is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. The recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG) is in development to treat high-risk and severely ill individuals infected with COVID-19.
Key features of the study:
- This report provides in-depth analysis of the global polyclonal antibody market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global polyclonal antibody market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global polyclonal antibody market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polyclonal antibody market.
Detailed Segmentation:
- Global Polyclonal Antibody Market, By Type:
- Primary Antibody
- Secondary Antibody
- Global Polyclonal Antibody Market, By Application:
- Academic Research
- Commercial
- Global Polyclonal Antibody Market, By Region:
- North America
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country:
- Latin America
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Academic Research
- Commercial
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Abcam plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- GenScript
- Merck KGaA.
- IgY Immune Technologies & Life Sciences Inc.
- Thermo Fisher Scientific Inc.
- Takara Bio Inc.
- Genway Biotech, Inc.
- Geno Technology Inc.
- DC Biosciences Ltd.
- Good Biotech Corp
- Rockland Immunochemicals, Inc.
- EpiGentek Group Inc.
- Innovagen AB
- GeneTex, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Content - Polyclonal Antibody Market
